As of November 6, 2026, TScan Therapeutics, Inc. is a publicly traded company (Nasdaq: TCRX); its largest reported holder is Lynx1 Capital Management LP, with 13.1% on Schedule 13G/A of August 14, 2026, then BVF Partners (9.99%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in TScan Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is TScan Therapeutics, Inc. a real, registered company?
- TScan Therapeutics, Inc. files with the SEC under CIK 1783328 (its SEC filings).
- Its shares are listed under the ticker TCRX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under TScan Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 2 exit or restructuring plans reported on Form 8-K, Item 2.05 (latest filed 2026-09-02).
- Leadership changes: the latest reported is Jason A. Amello, Chief Financial Officer (Form 8-K filed 2026-09-02). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Readout Capital, LP (filed 2026-09-25).
Who are TScan Therapeutics, Inc.'s owners and officers?
TScan Therapeutics, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-09-25).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-09-25 | Readout Capital, LP | 5.4% |
| Schedule 13G/A, 2026-08-14 | Lynx1 Capital Management LP | 13.1% |
| Schedule 13G/A, 2026-08-14 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2025-08-14 | Lynx1 Capital Management LP | 15% |
| Schedule 13G/A, 2025-08-12 | Adage Capital Management, L.P. | 2.52% |
| Schedule 13G/A, 2025-07-16 | Blackrock, Inc. | 1.8% |
Questions about who owns TScan Therapeutics, Inc.
Who owns TScan Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of TScan Therapeutics, Inc.: Lynx1 Capital Management LP (13.1%, Schedule 13G/A, filed 2026-08-14), Bvf Partners L P/Il (9.99%, Schedule 13G/A, filed 2026-08-14) and Readout Capital, LP (5.4%, Schedule 13G, filed 2026-09-25).
Who are the largest shareholders of TScan Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of TScan Therapeutics, Inc. on this page are Lynx1 Capital Management LP (13.1%), Bvf Partners L P/Il (9.99%) and Readout Capital, LP (5.4%).
When did Lynx1 Capital Management LP buy into TScan Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G/A, filed 2025-08-14, reporting 15%; its latest, Schedule 13G/A filed 2026-08-14, reports 13.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on TScan Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on TScan Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TScan Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-02 | Jason A. Amello | Chief Financial Officer | departed | 2026-09-02 |
| Form 8-K, 2026-04-02 | Leiden Dworak | Vice President | departed | 2026-04-10 |
| Form 8-K, 2026-04-02 | Jason A. Amello | Chief Financial Officer | appointed | 2026-04-10 |
Which insiders own TScan Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 15,956,564 shares (66.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-23).
- Lynx1 Capital Management LP, a 10% owner: 15,956,564 shares (66.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-23).
- , the chief executive and a director: 1,049,767 shares (4.4% of shares outstanding) (Form 4, 2026-10-02).
- Zoran Zdraveski: 304,716 shares (1.3% of shares outstanding) (Form 4, 2026-10-02).
Shares outstanding: 23,976,942 as of 2022-03-04, from the company's latest SEC cover page.
How much has TScan Therapeutics, Inc. raised?
No fundraising or offering filing from TScan Therapeutics, Inc. is on file with us.
Red flags found
2 exit or restructuring plans on Form 8-K (latest Form 8-K, 2026-09-02).
Keep reading
More on TScan Therapeutics, Inc. and the records around it.
TScan Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Leadership changes Sep 2026
- Layoff notices Sep 2026
Companies that share a holder
- Readout Capital, LP also filed stake reports on 1 other company: PRECISION BIOSCIENCES INC (Aug 2025)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/tscan-therapeutics